Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NexStent launches in Europe

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific will distribute EndoTex' carotid stent for use with its Monorail delivery system in Europe, according to April 13 announcements from the firms. EndoTex plans to submit a PMA covering the use of NexStent in conjunction with Boston Scientific's FilterWire embolic protection device this summer, with approval expected in the first quarter of 2006. Boston Scientific has agreed to acquire EndoTex upon the completion of certain regulatory milestones (1"The Gray Sheet" May 26, 2003, p. 26)...

You may also be interested in...



Boston Scientific Extends EndoTex Purchase Option; NexStent Evaluated

EndoTex Interventional Systems is planning an early 2004 launch of its self-expanding NexStent carotid stent outside the U.S., using Boston Scientific as exclusive distributor under an extended agreement between the firms

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel